

Attorney Docket No. 9052-221

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Peter Stockley et al.
 Application No.: 10/533,979
 PCT Application No.: PCT/GB2003/004798
 Filed November 5, 2003
 For: NUCLEIC ACID LIGANDS AND USES THEREOF

Confirmation No. 8946
 June 5, 2006

Mail Stop PCT
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450


**INFORMATION DISCLOSURE STATEMENT
 PURSUANT TO 37 C.F.R. § 1.97(b)**

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. Copies of the search reports in corresponding applications GB 0225833.3 and PCT/GB03/04798 are enclosed for the Examiner's convenience. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. §1.56 and Section 609 of the MPEP.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,




Shawna Cannon Lemon
 Registration No. 53,888

Myers Bigel Sibley & Sajovec, P.A.
 P. O. Box 37428, Raleigh, NC 27627
 Telephone: (919) 854-1400
 Facsimile: (919) 854-1401
 Customer No. 20792

CERTIFICATION OF TRANSMISSION UNDER 37 CFR § 1.8

I hereby certify that this correspondence is being facsimile transmitted or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below:

Signature: 
 Typed or Printed Name of Person Signing Certificate: Sarah Abraham

Date: June 5, 2006

Substitute form 1449A/PTO		C mplete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/533,979
		Filing Date	
		First Named Inventor	Peter Stockley
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	1	of	2
		Attorney Docket Number	9052-221

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
	1.	US-5,270,163	12-14-1993	Gold et al.	
	2.	US-5,475,096	12-12-1995	Gold et al.	
	3.	US-5,756,291	05-26-1998	Griffin et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code Number Kind Code (if known)				
	4.	DE 19916417 A1	10-19-2000	Schering AG		
	5.	EP 0533838 B1	12-03-1997	Nexstar Pharmaceuticals, Inc.		
	6.	WO 0109156 A1	08-02-2001	Nexstar Pharmaceuticals, Inc.		
	7.	WO 0188123 A1	11-22-2001	Isis Innovation Limited		
	8.	WO 0192566 A2	12-06-2001	Noxxon Pharma AG		
	9.	WO 0207762 A1	01-31-2002	Human Genome Sciences Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/533,979
		Filing Date	
		First Named Inventor	Peter Stockley
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	2	of	2
		Attorney Docket Number	9052-221

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	10.	YLERA, F, et al., Selection of RNA Aptamers to the Alzheimer's Disease Amyloid Peptide, Biochemical and Biophysical Research Communications (2002) 1583-1588, 290	
	11.	IVANOVA, M I, et al., Role of the C-Terminal 28 Residues of beta2-Microglobulin in Amyloid Fibril Formation, Biochemistry (2003) 13536-13540, 42	
	12.	SUNDE, M & Blake, C C, From the globular to the fibrous state: protein structure-and structural conversion in amyloid formation, Q Rev Biophys (1998) 1-39, 31:1	
	13.	FINK, A L Protein aggregation: folding aggregates, inclusion bodies and amyloid, Fold Des. (1998) R9-R23, 3	
	14.	KELLY, J W, The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways, Curr. Opin. Struct. Biol., (1998), 101-106, 8	
	15.	SELKOE, D J, Normal and abnormal biology of the beta-amyloid precursor protein, Ann. Rev. Neurosci. (1994) 489-517, 17	
	16.	ROCHET, J-C, et al. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein, Biochem. (2000) 10619-10626, 39	
	17.	BUCCIANINI, M, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases, Nature (2002) 507-511, 416	
	18.	WALSH, D M, et al., Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition, Biochem Soc Trans (2002) 552-557 30:4	
	19.	DOBSON, C.M., Protein misfolding, evolution and disease, Trends in Biochemical Sciences (1999) 329-332, 24	
	20.	CHECK, E, Nerve inflammation halts trial for Alzheimer's drug, Nature (2002) 462, 415-	
	21.	GEJYO, F, et al., Serum levels of beta2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis, New Eng. J. Med. (1986) 585-586, 314	
	22.	GEJYO, F, et al., A new form of amyloid protein associated with chronic hemodialysis was identified as beta2-microglobulin, Biochem Biophys Res Commun (1985) 701-706, 129:3	
	23.	JAMES, W, Aptamers, Nucleic Acids Structure and Mapping, Encyclopaedia of Analytical Chemistry. R A Mayors (Ed) 4848-4871	
	24.	RUSCONI, C P, et al. RNA aptamers as reversible antagonists of coagulation factor Ixa, Nature (2002) 90-94, 419	
	25.	YLERA, F, et al., Selection of RNA aptamers to the Alzheimer's disease amyloid peptide, BBRC (2002) 1583-1588, 290	
	26.	JONES, S, et al., Amyloid-forming peptides from beta2-microglobulin-Insights into the mechanism of fibril formation in vitro, J. Mol. Biol. (2003) 249-257, 325	
	27.	YAMAGUCHI, I, et al., Apolipoprotein E inhibits the depolymerization of beta2-microglobulin-related amyloid fibrils at a neutral pH, Biochemistry (2001) 8499-8507, 40	
	28.	McPARLAND, V J, et al., Partially unfolded states of beta2-microglobulin and amyloid formation in vitro, Biochem. (2000), 8735-8746, 39	
	29.	KAD, N M, et al., Beta2-microglobulin and its deamidated variant, N17D form amyloid fibrils with a range of morphologies in vitro, J. Mol. Biol. (2001) 559-571, 313	
	30.	COX, J C, et al., Automated RNA selection, Biotechnol. Prog. (1998) 845-850, 14	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.